Patients' characteristics at presentation
| Characteristic . | Patients With Deletions (n = 16) . | Patients Without Deletions (n = 39*) . |
|---|---|---|
| Sex (M/F) | 9/7 | 23/16 |
| Median age, y (range) | 54 (9-75) | 47 (17-82) |
| No. (%) with splenomegaly | 8 (50.0) | 27 (67.5) |
| White blood cell count (×109/L) | 223 ± 180 | 170 ± 129 |
| Hemoglobin (g/L) | 101.4 ± 19.8 | 113.1 ± 21.1 |
| Platelet count (×109/L) | 412 ± 273 | 445 ± 258 |
| Peripheral blood blast cells | ||
| No. (%) with >2% blast cells | 7 (44) | 3 (34) |
| White blood cells (%) | 4.79 ± 6.64 | 4.02 ± 9.55 |
| No. (%) in blast crisis/accelerated phase at presentation | 2 (12.5) | 2 (5.0) |
| No. (%) in chronic phase | 14 (87.5) | 38 (95.0) |
| Sokal high | 6 (37.5) | 15 (39.5) |
| Sokal medium | 4 (25.0) | 9 (26.7) |
| Sokal low | 4 (25.0) | 12 (31.6) |
| Treatment type, no. (%) | ||
| Interferon and chemotherapy | 5 (31) | 28 (70) |
| Chemotherapy alone | 11 (69) | 11 (28) |
| Bone marrow transplantation† | 3 (19)† | 11 (28)‡ |
| Karyotype, no. (%)‡ | ||
| Standard Ph | 6 (38) | 28 (70) |
| Variant Ph | 10 (62) | 11 (30) |
| Additional abnormalities | 2 (12.5) | 3 (7.5) |
| Characteristic . | Patients With Deletions (n = 16) . | Patients Without Deletions (n = 39*) . |
|---|---|---|
| Sex (M/F) | 9/7 | 23/16 |
| Median age, y (range) | 54 (9-75) | 47 (17-82) |
| No. (%) with splenomegaly | 8 (50.0) | 27 (67.5) |
| White blood cell count (×109/L) | 223 ± 180 | 170 ± 129 |
| Hemoglobin (g/L) | 101.4 ± 19.8 | 113.1 ± 21.1 |
| Platelet count (×109/L) | 412 ± 273 | 445 ± 258 |
| Peripheral blood blast cells | ||
| No. (%) with >2% blast cells | 7 (44) | 3 (34) |
| White blood cells (%) | 4.79 ± 6.64 | 4.02 ± 9.55 |
| No. (%) in blast crisis/accelerated phase at presentation | 2 (12.5) | 2 (5.0) |
| No. (%) in chronic phase | 14 (87.5) | 38 (95.0) |
| Sokal high | 6 (37.5) | 15 (39.5) |
| Sokal medium | 4 (25.0) | 9 (26.7) |
| Sokal low | 4 (25.0) | 12 (31.6) |
| Treatment type, no. (%) | ||
| Interferon and chemotherapy | 5 (31) | 28 (70) |
| Chemotherapy alone | 11 (69) | 11 (28) |
| Bone marrow transplantation† | 3 (19)† | 11 (28)‡ |
| Karyotype, no. (%)‡ | ||
| Standard Ph | 6 (38) | 28 (70) |
| Variant Ph | 10 (62) | 11 (30) |
| Additional abnormalities | 2 (12.5) | 3 (7.5) |
Plus ± minus values are mean ± SD.
For hemoglobin, data were obtained for 38 patients; for platelet count, 39 patients; and for >2% blasts, 38 patients. Sokal ratio was calculated for 36 patients.
Two allogeneic and 1 autologous transplantations were done in patients with deletions, and 9 allogeneic and 2 autologous transplantations were done in patients without deletions.
Eleven (68%) of patients with deletions and 11 (28%) of those without deletions had a karyotype analysis at presentation.